BIOMAT Database Logo BIOMAT Database Logo

[Continuous arterial infusion of protease inhibitor with supplementary therapy for the patients with severe acute pancreatitis--clinical effect of arterial injection of ulinastatin]. 1998

H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Department of Internal Medicine, National Health Insurance Organization Minamitama Hospital, Tokyo.

We treated five patients with severe acute pancreatitis by continuous arterial infusion (CAI) of protease inhibitor, nafamostat mesilate. Arterial injection (AI) of ulinastatin was performed in four cases and AI of antibiotics (IPM/CS) was done in one case, as supplemental therapies of CAI. Abdominal pain disappeared in 7.9 hours on the average, abdominal tenderness disappeared in 5.0 days and laboratory data lately recovered. All five cases treated by these therapies were cured without hemodialysis or surgical treatment in acute phase. AI of ulinastatin through arterial infusion catheter is pharmacokinetically more effective, because it yields a relatively high concentration of the drug at the acting site when compared with that of intravenous injection. Furthermore ulinastatin inhibits different types of protease from nafamostat mesilate. Therefore the clinical effect of CAI of nafamostat mesilate is enhanced by the combined therapy with AI of ulinastatin. It is also suggested that arterial injection of ulinastatin might be effective for the control of abdominal pain and that arterial injection of antibiotics might have an advantage on prevention of infectious pancreatic necrosis.

UI MeSH Term Description Entries
D007261 Infusions, Intra-Arterial Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease. Infusions, Regional Arterial,Infusions, Intra Arterial,Infusions, Intraarterial,Arterial Infusion, Intra,Arterial Infusion, Regional,Arterial Infusions, Intra,Arterial Infusions, Regional,Infusion, Intra Arterial,Infusion, Intra-Arterial,Infusion, Intraarterial,Infusion, Regional Arterial,Intra Arterial Infusion,Intra Arterial Infusions,Intra-Arterial Infusion,Intra-Arterial Infusions,Intraarterial Infusion,Intraarterial Infusions,Regional Arterial Infusion,Regional Arterial Infusions
D007269 Injections, Intra-Arterial Delivery of drugs into an artery. Injections, Intraarterial,Intra-Arterial Injections,Intraarterial Injections,Injection, Intra-Arterial,Injection, Intraarterial,Injections, Intra Arterial,Intra Arterial Injections,Intra-Arterial Injection,Intraarterial Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010195 Pancreatitis INFLAMMATION of the PANCREAS. Pancreatitis is classified as acute unless there are computed tomographic or endoscopic retrograde cholangiopancreatographic findings of CHRONIC PANCREATITIS (International Symposium on Acute Pancreatitis, Atlanta, 1992). The two most common forms of acute pancreatitis are ALCOHOLIC PANCREATITIS and gallstone pancreatitis. Acute Edematous Pancreatitis,Acute Pancreatitis,Pancreatic Parenchyma with Edema,Pancreatic Parenchymal Edema,Pancreatitis, Acute,Pancreatitis, Acute Edematous,Peripancreatic Fat Necrosis,Acute Edematous Pancreatitides,Acute Pancreatitides,Edema, Pancreatic Parenchymal,Edematous Pancreatitides, Acute,Edematous Pancreatitis, Acute,Fat Necrosis, Peripancreatic,Necrosis, Peripancreatic Fat,Pancreatic Parenchymal Edemas,Pancreatitides, Acute,Pancreatitides, Acute Edematous,Parenchymal Edema, Pancreatic,Peripancreatic Fat Necroses
D011480 Protease Inhibitors Compounds which inhibit or antagonize biosynthesis or actions of proteases (ENDOPEPTIDASES). Antiprotease,Endopeptidase Inhibitor,Endopeptidase Inhibitors,Peptidase Inhibitor,Peptidase Inhibitors,Peptide Hydrolase Inhibitor,Peptide Hydrolase Inhibitors,Peptide Peptidohydrolase Inhibitor,Peptide Peptidohydrolase Inhibitors,Protease Antagonist,Protease Antagonists,Antiproteases,Protease Inhibitor,Antagonist, Protease,Antagonists, Protease,Hydrolase Inhibitor, Peptide,Hydrolase Inhibitors, Peptide,Inhibitor, Endopeptidase,Inhibitor, Peptidase,Inhibitor, Peptide Hydrolase,Inhibitor, Peptide Peptidohydrolase,Inhibitor, Protease,Inhibitors, Endopeptidase,Inhibitors, Peptidase,Inhibitors, Peptide Hydrolase,Inhibitors, Peptide Peptidohydrolase,Inhibitors, Protease,Peptidohydrolase Inhibitor, Peptide,Peptidohydrolase Inhibitors, Peptide
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D006023 Glycoproteins Conjugated protein-carbohydrate compounds including MUCINS; mucoid, and AMYLOID glycoproteins. C-Glycosylated Proteins,Glycosylated Protein,Glycosylated Proteins,N-Glycosylated Proteins,O-Glycosylated Proteins,Glycoprotein,Neoglycoproteins,Protein, Glycosylated,Proteins, C-Glycosylated,Proteins, Glycosylated,Proteins, N-Glycosylated,Proteins, O-Glycosylated
D006146 Guanidines A family of iminourea derivatives. The parent compound has been isolated from mushrooms, corn germ, rice hulls, mussels, earthworms, and turnip juice. Derivatives may have antiviral and antifungal properties.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Continuous arterial infusion of protease inhibitor for severe acute pancreatitis.
June 1989, Gastroenterologia Japonica,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
[Continuous regional arterial infusion of the protease inhibitor for severe acute pancreatitis].
January 2020, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
[Continuous regional arterial infusion of protease inhibitor and antibiotic for severe acute pancreatitis].
November 2004, Nihon rinsho. Japanese journal of clinical medicine,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Effect of continuous arterial infusion of protease inhibitor on experimental acute pancreatitis.
August 1989, Gastroenterologia Japonica,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Successful treatment of severe acute pancreatitis by the combination therapy of continuous arterial infusion of a protease inhibitor and continuous hemofiltration.
August 2001, Journal of gastroenterology and hepatology,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Continuous regional arterial infusion therapy with gabexate mesilate for severe acute pancreatitis.
November 2008, World journal of gastroenterology,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
[A case of severe acute pancreatitis successfully treated by continuous arterial infusion of a protease inhibitor].
October 1994, Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Continuous regional arterial infusion of protease inhibitor and antibiotics in acute necrotizing pancreatitis.
April 1996, American journal of surgery,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Vascular access system for continuous arterial infusion of a protease inhibitor in acute necrotizing pancreatitis.
January 1999, Cardiovascular and interventional radiology,
H Matsukawa, and A Hara, and T Ito, and K Fukui, and K Sato, and M Ichikawa, and M Yoshioka, and H Seki, and K Yamataka, and K Takizawa, and S Okuda, and N Shiraga
Continuous arterial infusion therapy for severe acute pancreatitis: correlation between CT arteriography and therapeutic effect.
January 1999, Journal of vascular and interventional radiology : JVIR,
Copied contents to your clipboard!